NHMRC Clinical Trials Centre
Established in 1988, the NHMRC Clinical Trials Centre (CTC) now has a diverse group of 150 researchers. We have earned an outstanding reputation for contributing to major advances in clinical care via our high-quality collaborative clinical trials research.
Clinical trials research determines how existing drugs and treatments can be used most effectively and explores promising new therapies. Trials answer questions such as:
Is it better for patients with various cancers to have chemotherapy, radiotherapy, or both?
How should patients with heart disease be best treated to reduce the risk of heart attacks or strokes?
What are the benefits and risks of providing higher or lower levels of extra oxygen to very premature newborn babies?
The answers to these types of trials questions have led to important advances in patient care, which have resulted in better health outcomes for patients globally.
For example, thousands of lives are saved each year as a result of new cholesterol treatments, and patients are living longer, better-quality lives as a result of improved therapies for breast, lung, bowel and other cancers.
Towards the futureWe will continue our efforts to make clinical trials an integral part of health care. We also plan to maintain and build our global collaborative ties with other research networks, universities, government, and industry, to answer important clinical questions in new therapy areas.
Sub-collections in this collection
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial Published 2021Summary The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease) investigates the effectiveness of angiotensin receptor blockers in addition to standard care compared to ...Preprint
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial Published 2021BackgroundSARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2 (ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key regulator of the renin-angiotensin system (RAS) and is responsible ...Article
Published 2021Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has seen a large number of clinical trials launched at unprecedented speed. We aimed to explore the landscape of COVID-19 trials in Australia, and to ...Article
Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study Published 2021Background: Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a ...Article